Mucinous cystadenocarcinoma causes: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
(→Causes) |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{Qurrat}}; {{Ammu}} | {{CMG}}; {{AE}} {{Qurrat}}; {{Ammu}} | ||
==Overview== | ==Overview== | ||
Mutations in the ''KRAS'' gene cause mucinous cystadenocarcinoma. | [[Mutations]] in the ''[[KRAS]]'' [[gene]] cause mucinous cystadenocarcinoma. | ||
==Causes== | ==Causes== | ||
* ''KRAS'' | * ''[[KRAS]]'' [[Mutations|mutation]]<nowiki/>s are found in mucinous carcinoma<nowiki/>s of [[ovary]].<ref>Ovary Epithelial tumors. Atlasgeneticsoncology (2016).http://atlasgeneticsoncology.org/Tumors/OvaryEpithTumID5230.html Accessed on February 29, 2016</ref><ref name="pmid12893203">{{cite journal |vauthors=Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, Soslow R, Venkatraman E, Boyd J |title=Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma |journal=Gynecol. Oncol. |volume=90 |issue=2 |pages=378–81 |date=August 2003 |pmid=12893203 |doi= |url=}}</ref><ref name="pmid16806438">{{cite journal |vauthors=Mayr D, Hirschmann A, Löhrs U, Diebold J |title=KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants |journal=Gynecol. Oncol. |volume=103 |issue=3 |pages=883–7 |date=December 2006 |pmid=16806438 |doi=10.1016/j.ygyno.2006.05.029 |url=}}</ref><ref name="pmid9118042">{{cite journal |vauthors=Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J |title=K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases |journal=Cancer |volume=79 |issue=8 |pages=1581–6 |date=April 1997 |pmid=9118042 |doi= |url=}}</ref> | ||
* Chronic luminal obstruction of the appendix may lead to cyst formation and due to continued mucin secretion by the mucosal epithelium may lead | * [[Chronic]] [[Lumen|luminal obstruction]] of the [[appendix]] may lead to [[Cyst|cyst formation]] and due to continued mucin secretion by the [[mucosal]] [[epithelium]], may lead to [[mucous]] [[cyst]] [[adenoma]] formation. | ||
* Hyperplastic lesions of epithelium with dysplasia may progress to mucin secreting cystadenocarcinomas.<ref name="pmid26492181">{{cite journal |vauthors=Carr NJ, Cecil TD, Mohamed F, Sobin LH, Sugarbaker PH, González-Moreno S, Taflampas P, Chapman S, Moran BJ |title=A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process |journal=Am. J. Surg. Pathol. |volume=40 |issue=1 |pages=14–26 |date=January 2016 |pmid=26492181 |doi=10.1097/PAS.0000000000000535 |url=}}</ref><ref name="pmid28746986">{{cite journal |vauthors=Carr NJ, Bibeau F, Bradley RF, Dartigues P, Feakins RM, Geisinger KR, Gui X, Isaac S, Milione M, Misdraji J, Pai RK, Rodriguez-Justo M, Sobin LH, van Velthuysen MF, Yantiss RK |title=The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei |journal=Histopathology |volume=71 |issue=6 |pages=847–858 |date=December 2017 |pmid=28746986 |doi=10.1111/his.13324 |url=}}</ref> | * [[Hyperplastic]] [[lesions]] of [[epithelium]] with [[dysplasia]] may progress to mucin secreting cystadenocarcinomas.<ref name="pmid26492181">{{cite journal |vauthors=Carr NJ, Cecil TD, Mohamed F, Sobin LH, Sugarbaker PH, González-Moreno S, Taflampas P, Chapman S, Moran BJ |title=A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process |journal=Am. J. Surg. Pathol. |volume=40 |issue=1 |pages=14–26 |date=January 2016 |pmid=26492181 |doi=10.1097/PAS.0000000000000535 |url=}}</ref><ref name="pmid28746986">{{cite journal |vauthors=Carr NJ, Bibeau F, Bradley RF, Dartigues P, Feakins RM, Geisinger KR, Gui X, Isaac S, Milione M, Misdraji J, Pai RK, Rodriguez-Justo M, Sobin LH, van Velthuysen MF, Yantiss RK |title=The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei |journal=Histopathology |volume=71 |issue=6 |pages=847–858 |date=December 2017 |pmid=28746986 |doi=10.1111/his.13324 |url=}}</ref> | ||
==Reference== | ==Reference== | ||
Latest revision as of 13:48, 1 May 2019
|
Mucinous cystadenocarcinoma Microchapters |
|
Differentiating Mucinous Cystadenocarcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Mucinous cystadenocarcinoma causes On the Web |
|
American Roentgen Ray Society Images of Mucinous cystadenocarcinoma causes |
|
Directions to Hospitals Treating Mucinous cystadenocarcinoma |
|
Risk calculators and risk factors for Mucinous cystadenocarcinoma causes |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Qurrat-ul-ain Abid, M.D.[2]; Ammu Susheela, M.D. [3]
Overview
Mutations in the KRAS gene cause mucinous cystadenocarcinoma.
Causes
- KRAS mutations are found in mucinous carcinomas of ovary.[1][2][3][4]
- Chronic luminal obstruction of the appendix may lead to cyst formation and due to continued mucin secretion by the mucosal epithelium, may lead to mucous cyst adenoma formation.
- Hyperplastic lesions of epithelium with dysplasia may progress to mucin secreting cystadenocarcinomas.[5][6]
Reference
- ↑ Ovary Epithelial tumors. Atlasgeneticsoncology (2016).http://atlasgeneticsoncology.org/Tumors/OvaryEpithTumID5230.html Accessed on February 29, 2016
- ↑ Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, Soslow R, Venkatraman E, Boyd J (August 2003). "Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma". Gynecol. Oncol. 90 (2): 378–81. PMID 12893203.
- ↑ Mayr D, Hirschmann A, Löhrs U, Diebold J (December 2006). "KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants". Gynecol. Oncol. 103 (3): 883–7. doi:10.1016/j.ygyno.2006.05.029. PMID 16806438.
- ↑ Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J (April 1997). "K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases". Cancer. 79 (8): 1581–6. PMID 9118042.
- ↑ Carr NJ, Cecil TD, Mohamed F, Sobin LH, Sugarbaker PH, González-Moreno S, Taflampas P, Chapman S, Moran BJ (January 2016). "A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process". Am. J. Surg. Pathol. 40 (1): 14–26. doi:10.1097/PAS.0000000000000535. PMID 26492181.
- ↑ Carr NJ, Bibeau F, Bradley RF, Dartigues P, Feakins RM, Geisinger KR, Gui X, Isaac S, Milione M, Misdraji J, Pai RK, Rodriguez-Justo M, Sobin LH, van Velthuysen MF, Yantiss RK (December 2017). "The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei". Histopathology. 71 (6): 847–858. doi:10.1111/his.13324. PMID 28746986.